Exclusive: Third death in China's popular but opaque trials revealed, this time in CAR-T

Recent reporting from Endpoints News, STAT, Stanford Law School, Gizmodo, and Fierce Biotech details a newly revealed death in a CAR-T trial in China, marking a third fatality linked to the nation's popular clinical trials. Coverage also addresses prior incidents, including a boy's death, two previously undisclosed deaths, and reports of brain tumors associated with gene therapy involving Huidagene. These developments have brought intense focus to investigator-initiated trials (IIT) within the country, raising urgent questions about transparency, trial strategy, and overall safety standards. The unfolding situation has generated significant analysis across multiple specialized outlets. STAT has published dedicated pieces dissecting Chinese trial strategy and examining the specific decisions made by Huidagene following the death of a young patient.

Fierce Biotech questions whether China's investigator-initiated trials can still be trusted in the wake of these undisclosed fatalities. Meanwhile, Stanford Law School and Gizmodo have framed the broader discussion around the inherent dangers of gene therapy, examining how these therapies are regulated and monitored when tragedies occur. This current wave of scrutiny builds on growing concern over transparency within China's booming biotechnology sector. Investigator-initiated trials often operate with less regulatory oversight and public disclosure than standard multi-center international trials, making safety events difficult to track. The disclosure of multiple deaths and adverse events such as brain tumors highlights systemic issues regarding how clinical trial data is communicated to the global scientific community and regulatory bodies.

Observers and industry stakeholders are watching to see how regulators, international experts, and Chinese institutions will respond to these revelations. Coverage does not yet specify what formal policy changes or institutional investigations will follow the disclosure of the third death. Further reporting will likely focus on whether transparency standards for investigator-initiated trials will be revised to prevent future undisclosed tragedies in gene and CAR-T therapies.